Skip to main content

Table 1 Patients and disease characteristics

From: GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Main characteristics (N = 15) N° (%)
Age, years
 Median (range) 52 (42–68)
Sex
 Male 9 (60)
 Female 6 (40)
ECOG performance status
 0 12 (80)
 1 3 (20)
Histological grade
 High 5 (33)
 Low 10 (67)
Time from CRS + HIPEC to relapse
 Median (range, months) 13 (5–36)
 ≤12 months 7 (47)
 >12 months 8 (53)
PCI at the time of CRS + HIPEC
 Median (range) 27 (8–39)
Completeness of cytoreduction
 CC-0 8 (53)
 CC-1 7 (47)
  1. CRS cytoreductive surgery; HIPEC hyperthermic intraperitoneal chemotherapy; PCI peritoneal carcinomatosis index; CC completeness of cytoreduction score